it was first described by ronald asherson in 1992 the syndrome exhibits thrombotic microangiopathy multiple organ thrombosis and in some cases tissue necrosis and is considered an extreme or catastrophic variant of the antiphospholipid syndrome caps has a mortality rate of about 50 with the establishment of a caps registry more has been learned about this syndrome but its cause remains unknown infection trauma medication and or surgery can be identified in about half the cases as a trigger it is thought that cytokines are activated leading to a cytokine storm with the potentially fatal consequences of organ failure a low platelet count is a common finding clinically the syndrome affects at least three organs and may affect many organs systems peripheral thrombosis may be encountered affecting veins and arteries intra abdominal thrombosis may lead to pain cardiovascular nervous kidney and lung system complications are common the affected individual may exhibit skin purpura and necrosis cerebral manifestations may lead to encephalopathy and seizures myocardial infarctions may occur strokes may occur due to the arterial clotting involvement death may result from multiple organ failure individuals with caps often exhibit a positive test to antilipid antibodies typically igg and may or may